bromantane vs semax
updated
bromantane (tier B) vs semax (tier B): what each is, why each got its grade, half-life and source counts side by side.
bromantane · tier B
a Russian antiasthenic CNS drug with older human studies in illness-related fatigue, incomplete modern replication, no traceable primary human half-life source, and in-competition WADA prohibition.
tier rationale
B-tier reflects a real approved-abroad drug history and multiple human studies, including a 728-patient multicenter asthenia report. It stays below A because the evidence is older, geographically concentrated, incompletely accessible, focused on diagnosed asthenia rather than healthy performance, and missing the kind of modern PK and long-term safety package expected for broad claims.
semax · tier B
russian nootropic. approved there, not here. for focus, stroke recovery, and cognitive decline. real mechanism, thin US trials.
tier rationale
B-tier because the evidence base is real but geographically and linguistically constrained. Russian regulatory approval for three indications, two decades of clinical use, confirmed BDNF mechanism. Held back from A-tier because Western clinical replication is limited and most primary literature requires Russian-language fluency to read. FDA's 503A process could change the U.S. compounding lane, but that would not be drug approval.
at a glance
| bromantane | semax | |
|---|---|---|
| tier | B | B |
| category | nootropic / longevity | nootropic / longevity |
| sources | 7 | 26 |
| claims evaluated | 4 | 6 |
| half-life | not structured; the repeated 11.21-hour human claim was not traced to an accessible primary PK source | minutes in plasma; effects persist for hours due to CNS penetration and BDNF induction cascade |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.